PL3096756T3 - Antagonisty receptora CRF1 do leczenia wrodzonego przerostu nadnerczy - Google Patents

Antagonisty receptora CRF1 do leczenia wrodzonego przerostu nadnerczy

Info

Publication number
PL3096756T3
PL3096756T3 PL15702917.4T PL15702917T PL3096756T3 PL 3096756 T3 PL3096756 T3 PL 3096756T3 PL 15702917 T PL15702917 T PL 15702917T PL 3096756 T3 PL3096756 T3 PL 3096756T3
Authority
PL
Poland
Prior art keywords
treatment
receptor antagonists
adrenal hyperplasia
congenital adrenal
crf1 receptor
Prior art date
Application number
PL15702917.4T
Other languages
English (en)
Inventor
Dimitri E. Grigoriadis
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52450623&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3096756(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of PL3096756T3 publication Critical patent/PL3096756T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL15702917.4T 2014-01-21 2015-01-21 Antagonisty receptora CRF1 do leczenia wrodzonego przerostu nadnerczy PL3096756T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461929941P 2014-01-21 2014-01-21
US201461981033P 2014-04-17 2014-04-17
US201462069155P 2014-10-27 2014-10-27
PCT/US2015/012315 WO2015112642A1 (en) 2014-01-21 2015-01-21 Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia

Publications (1)

Publication Number Publication Date
PL3096756T3 true PL3096756T3 (pl) 2024-10-28

Family

ID=52450623

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15702917.4T PL3096756T3 (pl) 2014-01-21 2015-01-21 Antagonisty receptora CRF1 do leczenia wrodzonego przerostu nadnerczy

Country Status (24)

Country Link
US (5) US20170020877A1 (pl)
EP (2) EP4450070A1 (pl)
JP (5) JP6585625B2 (pl)
KR (2) KR102258522B1 (pl)
CN (2) CN111228274A (pl)
AU (4) AU2015209452C1 (pl)
BR (1) BR112016016975B1 (pl)
CA (2) CA3155599A1 (pl)
DK (1) DK3096756T3 (pl)
ES (1) ES2984706T3 (pl)
FI (1) FI3096756T3 (pl)
HR (1) HRP20241046T1 (pl)
HU (1) HUE068315T2 (pl)
IL (5) IL317035A (pl)
LT (1) LT3096756T (pl)
MX (3) MX389004B (pl)
NZ (1) NZ722122A (pl)
PL (1) PL3096756T3 (pl)
PT (1) PT3096756T (pl)
RS (1) RS65839B1 (pl)
RU (1) RU2718918C2 (pl)
SI (1) SI3096756T1 (pl)
SM (1) SMT202400361T1 (pl)
WO (1) WO2015112642A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3096756T3 (fi) * 2014-01-21 2024-08-14 Neurocrine Biosciences Inc Crf1-reseptorin antagonisteja synnynnäisen lisämunuaisen liikakasvun hoitoon
US9688754B2 (en) 2014-02-20 2017-06-27 Alder Biopharmaceuticals, Inc. Anti-ACTH antibodies and use thereof
CA3039026A1 (en) 2016-09-07 2018-03-15 The Regents Of The University Of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
KR20250022913A (ko) * 2017-08-14 2025-02-17 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
EP4438124A3 (en) * 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
JP7532328B2 (ja) * 2018-12-07 2024-08-13 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 先天性副腎過形成を処置するためのｃｒｆ１受容体アンタゴニスト、その医薬製剤および固体形態
TW202446384A (zh) * 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
CA3147891A1 (en) * 2019-07-19 2021-01-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
WO2021062246A1 (en) * 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
CR20220624A (es) * 2020-06-10 2023-07-06 Sanofi Sa Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
AU2021324839B2 (en) * 2020-08-12 2024-02-29 Spruce Biosciences, Inc. Methods and compositions for treating polycystic ovary syndrome
MD20210019A2 (ro) 2021-04-12 2022-10-31 Максим МАСЮТИН Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4949582B1 (pl) 1969-01-20 1974-12-27
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
FR2692893B1 (fr) 1992-06-24 1994-09-02 Sanofi Elf Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
CA2265672C (en) 1996-09-16 2008-12-02 Du Pont Pharmaceuticals Company Pyrazinones and triazinones and their derivatives thereof
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
DE69818248T2 (de) 1997-04-22 2004-06-17 Janssen Pharmaceutica N.V. Chinolin- und chinazolin-derivate als crf antagonisten
WO1999010350A1 (en) 1997-08-22 1999-03-04 Du Pont Pharmaceuticals Company NITROGEN SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLES AS CORTICOTROPIN RELEASING HORMONE ANTAGONISTS
US6531475B1 (en) 1998-11-12 2003-03-11 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
JP2003528802A (ja) 1999-04-02 2003-09-30 ニューロゲン コーポレイション Ｎ−ベンゾイミダゾリルメチル−及びｎ−インドリルメチル−ベンズアミド並びにｃｒｆ調節物質としてのそれらの使用
FR2796380B3 (fr) 1999-07-15 2001-08-17 Sanofi Synthelabo Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant
FR2802530B1 (fr) 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
BRPI0507609A (pt) 2004-02-13 2007-07-03 Pfizer Prod Inc combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
ES2326827T3 (es) 2004-10-19 2009-10-20 Smithkline Beecham (Cork) Limited Anatagonistas del receptor de crf y metodos relacionados.
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
PT1869049E (pt) 2005-03-21 2009-05-26 Lilly Co Eli Compostos de imidazopiridazina
EP1879896A1 (en) 2005-04-05 2008-01-23 Eli Lilly And Company Imidazopyridazine compounds
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US20090234117A1 (en) 2005-05-27 2009-09-17 Toshihiko Kashiwagi Pyrazolopyrimidine Derivative
CA2627923C (en) 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
JPWO2007069565A1 (ja) 2005-12-12 2009-05-21 小野薬品工業株式会社 二環式複素環化合物
JPWO2007069671A1 (ja) 2005-12-15 2009-05-21 小野薬品工業株式会社 二環式複素環化合物
PL1982178T3 (pl) 2006-02-07 2014-02-28 Phenoquest Ag Sposoby leczenia zaburzeń afektywnych
EP1834641A1 (en) 2006-03-16 2007-09-19 Sanofi-Aventis Use of CRF1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia
RU2008150624A (ru) 2006-05-22 2010-06-27 Ванда Фармасьютиклз, Инк. (Us) Лечение депрессивных расстройств
ES2350282T3 (es) 2006-09-20 2011-01-20 Eli Lilly And Company Tiazol pirazolopirimidinas como antagonistas del receptor de crf1.
KR101088196B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 티오펜 피라졸로피리미딘 화합물
EP2088861A4 (en) 2006-10-25 2010-07-07 Takeda Pharmaceutical Benzimidazole compounds
WO2008082003A1 (en) 2006-12-29 2008-07-10 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds having crf antagonistic activity
WO2008083070A1 (en) 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
WO2009008552A1 (en) 2007-07-11 2009-01-15 Taisho Pharmaceutical Co., Ltd. 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
WO2009144632A1 (en) 2008-05-30 2009-12-03 Pfizer Limited Novel compounds
US7932256B2 (en) 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
US8436000B2 (en) 2008-07-31 2013-05-07 Bristol-Myers Squibb Company Substituted carbamate derivatives as modulators of corticotropin-releasing factor receptor activity
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
DE202009018581U1 (de) 2008-11-03 2012-03-02 Synthes Gmbh Einstellbare Stangenanordnung
WO2010096426A2 (en) 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
HUP0900267A2 (en) 2009-04-30 2011-03-28 Sanofi Aventis Process for preparing of thiazole amines and intermediates thereof
WO2011043387A1 (ja) 2009-10-08 2011-04-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
CN102753527B (zh) 2010-02-02 2014-12-24 诺华股份有限公司 用作crf受体拮抗剂的环己基酰胺衍生物
IL308807B2 (en) 2012-04-13 2025-08-01 Epizyme Inc Combination therapy for treating cancer
EP2841595A2 (en) * 2012-04-23 2015-03-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
US20150094310A1 (en) 2012-04-23 2015-04-02 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity
FI3096756T3 (fi) 2014-01-21 2024-08-14 Neurocrine Biosciences Inc Crf1-reseptorin antagonisteja synnynnäisen lisämunuaisen liikakasvun hoitoon
WO2016065177A1 (en) 2014-10-22 2016-04-28 The Trustees Of The University Of Pennsylvania Method of treating depression and other stress related disorders
EP3253752B1 (en) 2015-02-06 2023-08-16 Neurocrine Biosciences, Inc. [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
CA2980811A1 (en) 2015-04-02 2016-10-06 Hmnc Value Gmbh Method of treatment using genetic predictors of a response to treatment with crhr1 antagonists
WO2018012066A1 (ja) * 2016-07-14 2018-01-18 株式会社コナミデジタルエンタテインメント ゲームシステム、端末装置及びプログラム
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
WO2018219804A1 (en) 2017-06-02 2018-12-06 Bayer Pharma Aktiengesellschaft Self-microemulsifying drug delivery systems
KR20250022913A (ko) 2017-08-14 2025-02-17 스프루스 바이오사이언시스 인코포레이티드 코티코트로핀 방출 인자 수용체 길항제
AU2018318990B2 (en) 2017-08-14 2023-01-05 Spruce Biosciences, Inc. Corticotropin releasing factor receptor antagonists
EP4438124A3 (en) * 2018-04-27 2024-12-18 Spruce Biosciences, Inc. Methods for treating testicular and ovarian adrenal rest tumors
TW202446384A (zh) 2018-12-07 2024-12-01 美商紐羅克里生物科學有限公司 用於治療先天性腎上腺增生之crf1受體拮抗劑、醫藥配方及其固體形式
CA3147891A1 (en) 2019-07-19 2021-01-28 Spruce Biosciences, Inc. Methods of treating congenital adrenal hyperplasia
WO2021062246A1 (en) 2019-09-27 2021-04-01 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
EP4069697B1 (en) 2019-12-04 2025-07-16 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
CR20220624A (es) 2020-06-10 2023-07-06 Sanofi Sa Antagonista del receptor crf1 para el tratamiento de la hiperplasia suprarrenal congénita
EP4203964A1 (en) 2020-08-26 2023-07-05 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use

Also Published As

Publication number Publication date
EP4450070A1 (en) 2024-10-23
AU2020207774B2 (en) 2022-08-04
CN106102740A (zh) 2016-11-09
US11311544B2 (en) 2022-04-26
AU2020207774A1 (en) 2020-08-06
PT3096756T (pt) 2024-08-26
US20210361659A1 (en) 2021-11-25
CN111228274A (zh) 2020-06-05
US20190231781A1 (en) 2019-08-01
EP3096756A1 (en) 2016-11-30
IL304134B1 (en) 2024-12-01
JP2024098001A (ja) 2024-07-19
CA3155599A1 (en) 2015-07-30
JP2020138978A (ja) 2020-09-03
US20240058342A1 (en) 2024-02-22
HUE068315T2 (hu) 2024-12-28
MX389004B (es) 2025-03-20
IL296683B1 (en) 2023-08-01
EP3096756B1 (en) 2024-06-12
IL246783B (en) 2021-10-31
JP6585625B2 (ja) 2019-10-02
JP2019081814A (ja) 2019-05-30
LT3096756T (lt) 2024-08-26
IL317035A (en) 2025-01-01
HRP20241046T1 (hr) 2024-11-08
JP7104743B2 (ja) 2022-07-21
IL304134A (en) 2023-09-01
DK3096756T3 (da) 2024-08-05
AU2015209452A1 (en) 2016-08-04
JP6936825B2 (ja) 2021-09-22
JP2017503030A (ja) 2017-01-26
IL286782A (en) 2021-10-31
AU2015209452B2 (en) 2020-05-07
NZ722122A (en) 2020-06-26
US20210137926A1 (en) 2021-05-13
KR102258522B1 (ko) 2021-05-31
MX2022000080A (es) 2022-02-03
IL296683B2 (en) 2023-12-01
IL296683A (en) 2022-11-01
AU2024219813A1 (en) 2024-10-10
KR20210064407A (ko) 2021-06-02
RS65839B1 (sr) 2024-09-30
RU2016133972A (ru) 2018-03-05
AU2015209452C1 (en) 2020-11-05
US11730739B2 (en) 2023-08-22
CA2936974A1 (en) 2015-07-30
SI3096756T1 (sl) 2024-09-30
BR112016016975A2 (pt) 2017-08-08
US10905690B2 (en) 2021-02-02
IL246783A0 (en) 2016-08-31
AU2022263460B2 (en) 2024-10-17
RU2020112197A (ru) 2020-05-21
JP2022010260A (ja) 2022-01-14
MX2021012539A (es) 2021-11-12
RU2718918C2 (ru) 2020-04-15
SMT202400361T1 (it) 2024-11-15
MX2016009499A (es) 2017-02-27
KR20160106176A (ko) 2016-09-09
IL304134B2 (en) 2025-04-01
AU2022263460A1 (en) 2022-12-08
WO2015112642A1 (en) 2015-07-30
FI3096756T3 (fi) 2024-08-14
RU2016133972A3 (pl) 2018-09-26
BR112016016975B1 (pt) 2022-12-27
ES2984706T3 (es) 2024-10-30
US20170020877A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
LT3096756T (lt) Crf1 receptoriaus antagonistai, skirti įgimtos antinksčių hiperplazijos gydymui
IL288321A (en) Methods for treating depression using orexin-2 receptor antagonists
IL253588A0 (en) History of bicyclic quinazolinones
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
LT3297631T (lt) Nk-1/nk-3 receptorių antagonistas, skirtas karščio pylimo gydymui
GB2580236B (en) Apparatus for treating runoff
IL258893A (en) Cgrp receptor antagonists
ZA201800452B (en) Cgrp receptor antagonists
IL258894A (en) Cgrp receptor antagonists
IL262921B (en) Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors